{
  "id": "F7jLqvX_0",
  "conversations": [
    {
      "from": "human",
      "value": "Hello",
      "language": "fi",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0
      },
      "expressive_label": 1,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Hello! How can I assist you today?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 1,
        "second_person_freq": 1,
        "token_count": 9,
        "self_ref_ratio": 0.1111111111111111,
        "second_person_ratio": 0.1111111111111111
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 1,
        "self_ref_ratio": 0.1111111111111111,
        "second_person_freq": 1,
        "second_person_ratio": 0.1111111111111111,
        "token_count": 9
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 4.5,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 1,
            "why": 0,
            "can_could": 1,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 1
          },
          "named_entities": {
            "GPE": 1
          }
        }
      }
    },
    {
      "from": "human",
      "value": "Do you know the guidelines from 2020 Guidelines for Management of Atrial Fibrillation ?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 1,
        "token_count": 14,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.07142857142857142
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 1,
        "second_person_ratio": 0.07142857142857142,
        "token_count": 14
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 14.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.8571428571428571
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 2
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Yes, I am familiar with the 2020 Guidelines for Management of Atrial Fibrillation. These guidelines were published by the European Society of Cardiology (ESC) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).\n\nThe guidelines cover a wide range of topics related to the management of atrial fibrillation, including diagnosis, assessment of stroke risk, treatment options, and follow-up care. Some of the key recommendations from the guidelines include:\n\n1. Assessment of stroke risk: The guidelines recommend using the CHA2DS2-VASc score to assess stroke risk in patients with atrial fibrillation, and suggest that anticoagulant therapy be considered for patients with a score of 1 or higher.\n2. Rate vs. rhythm control: The guidelines suggest that rate control may be a more appropriate strategy than rhythm control for many patients with atrial fibrillation, especially those with persistent or long-standing persistent AF. However, rhythm control may be preferred in certain patient populations.\n3. Anticoagulation therapy: The guidelines recommend the use of oral anticoagulant therapy (OAC) for stroke prevention in patients with AF, and suggest that non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over vitamin K antagonists (VKAs) for most patients.\n4. Catheter ablation: The guidelines suggest that catheter ablation may be considered for patients with symptomatic paroxysmal or persistent AF who have failed antiarrhythmic drug therapy or who have significant symptoms despite adequate rate control.\n\nThese are just a few of the many recommendations provided in the 2020 Guidelines for Management of Atrial Fibrillation. I hope this information is helpful!",
      "language": "en",
      "sentiment": {
        "neg": 0.062,
        "neu": 0.854,
        "pos": 0.084,
        "compound": 0.7291
      },
      "core_lexical": {
        "self_ref_freq": 2,
        "second_person_freq": 0,
        "token_count": 287,
        "self_ref_ratio": 0.006968641114982578,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 37,
        "adj_adv_ratio": 0.1289198606271777,
        "self_ref_freq": 2,
        "self_ref_ratio": 0.006968641114982578,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 287
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 20.5,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.5827814569536424
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 1,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 14,
            "VBD": 1,
            "VBN": 8,
            "VBG": 2,
            "VB": 5,
            "VBZ": 1
          },
          "named_entities": {
            "ORGANIZATION": 10,
            "GPE": 1
          }
        }
      }
    },
    {
      "from": "human",
      "value": "Okay, I see you are well informed.\n\nFrom these guidelines, can you tell me how the ESC suggest the screening of new patients ?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.846,
        "pos": 0.154,
        "compound": 0.4588
      },
      "core_lexical": {
        "self_ref_freq": 2,
        "second_person_freq": 2,
        "token_count": 27,
        "self_ref_ratio": 0.07407407407407407,
        "second_person_ratio": 0.07407407407407407
      },
      "lexical_features": {
        "adj_adv_freq": 2,
        "adj_adv_ratio": 0.07407407407407407,
        "self_ref_freq": 2,
        "self_ref_ratio": 0.07407407407407407,
        "second_person_freq": 2,
        "second_person_ratio": 0.07407407407407407,
        "token_count": 27
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 13.5,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 1,
            "why": 0,
            "can_could": 1,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 3,
            "VBN": 1,
            "VB": 1
          },
          "named_entities": {
            "GPE": 1,
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 1
    },
    {
      "from": "gpt",
      "value": "Yes, the ESC guidelines do provide recommendations for screening new patients with suspected atrial fibrillation. The guidelines recommend the following approach:\n\n1. Symptom assessment: All patients with suspected atrial fibrillation should undergo a thorough clinical assessment, including a detailed history and physical examination to identify symptoms of atrial fibrillation such as palpitations, shortness of breath, fatigue, or dizziness.\n2. Electrocardiogram (ECG): The guidelines recommend that all patients with suspected atrial fibrillation undergo a 12-lead ECG to confirm the diagnosis. In addition, ambulatory ECG monitoring (Holter or event monitoring) may be considered for patients with suspected paroxysmal atrial fibrillation.\n3. Risk factor assessment: The guidelines suggest that all patients with newly diagnosed atrial fibrillation undergo a comprehensive risk factor assessment, including evaluation for hypertension, diabetes, heart failure, coronary artery disease, and valvular heart disease.\n4. Imaging: The guidelines recommend that all patients with newly diagnosed atrial fibrillation undergo a transthoracic echocardiogram (TTE) to evaluate left ventricular function, left atrial size, and the presence of valvular heart disease.\n\nBy following this approach, clinicians can accurately diagnose and assess the severity of atrial fibrillation in new patients and determine the most appropriate treatment strategies based on individual patient characteristics and risk factors.",
      "language": "en",
      "sentiment": {
        "neg": 0.085,
        "neu": 0.805,
        "pos": 0.11,
        "compound": 0.8625
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 235,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 38,
        "adj_adv_ratio": 0.16170212765957448,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 235
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 21.363636363636363,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.6142857142857143
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 1,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 1,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 5,
            "VB": 9,
            "VBG": 4,
            "VBN": 4,
            "VBZ": 1,
            "VBD": 1
          },
          "named_entities": {
            "ORGANIZATION": 5,
            "PERSON": 2
          }
        }
      }
    },
    {
      "from": "human",
      "value": "Thank you.\n\nFrom the guidelines, what score does the ESC suggest using for the risk factor assessment ?",
      "language": "en",
      "sentiment": {
        "neg": 0.102,
        "neu": 0.777,
        "pos": 0.121,
        "compound": 0.1027
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 1,
        "token_count": 20,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.05
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 1,
        "second_person_ratio": 0.05,
        "token_count": 20
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 10.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 1,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 1,
            "VBP": 1,
            "VBG": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 1,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "The ESC guidelines recommend using the CHA2DS2-VASc score for risk factor assessment in patients with atrial fibrillation. This scoring system takes into account various risk factors for stroke and assigns a score to each factor. The components of the CHA2DS2-VASc score are as follows:\n\n* C: Congestive heart failure or left ventricular dysfunction (1 point)\n* H: Hypertension (1 point)\n* A2: Age â‰¥75 years (2 points)\n* D: Diabetes mellitus (1 point)\n* S2: Prior stroke or transient ischemic attack (2 points)\n* V: Vascular disease (1 point)\n* A: Age 65-74 years (1 point)\n* Sc: Female sex (1 point)\n\nThe maximum CHA2DS2-VASc score is 9 points, with higher scores indicating a greater risk of stroke. According to the guidelines, anticoagulation therapy should be considered for patients with a CHA2DS2-VASc score of 1 or higher. However, the decision to initiate anticoagulation therapy should be individualized and take into account other factors such as bleeding risk and patient preferences.",
      "language": "en",
      "sentiment": {
        "neg": 0.098,
        "neu": 0.834,
        "pos": 0.068,
        "compound": -0.5372
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 193,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 21,
        "adj_adv_ratio": 0.10880829015544041,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 193
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 38.6,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.6732673267326733
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 1,
            "contrast": 1,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 4,
            "VBG": 5,
            "VBZ": 9,
            "VB": 5,
            "VBD": 1,
            "VBN": 2
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      }
    },
    {
      "from": "human",
      "value": "What are the limits of this score, according to the guidelines ?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 13,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 13
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 13.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 1,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 1,
            "VBG": 1
          },
          "named_entities": {}
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "According to the ESC guidelines, the CHA2DS2-VASc score has some limitations that should be taken into account when assessing stroke risk in patients with atrial fibrillation. Some of the limitations include:\n\n1. Limited predictive accuracy in low-risk patients: The CHA2DS2-VASc score is most useful for identifying patients at high risk of stroke. However, the score may not accurately predict stroke risk in patients with a low score (e.g., 0 or 1), as the majority of strokes occur in patients with higher scores.\n2. Lack of consideration of other risk factors: The CHA2DS2-VASc score only takes into account certain risk factors for stroke, such as age, sex, and comorbidities. Other factors, such as biomarkers or imaging findings, may also be important predictors of stroke risk.\n3. Limited generalizability: The CHA2DS2-VASc score was developed and validated primarily in populations of patients with non-valvular atrial fibrillation. Its applicability in other populations, such as those with valvular heart disease or atrial flutter, is uncertain.\n4. Limited consideration of bleeding risk: The CHA2DS2-VASc score does not take into account bleeding risk, which is an important consideration when deciding whether to initiate anticoagulation therapy in patients with atrial fibrillation.\n\nDespite these limitations, the CHA2DS2-VASc score remains a useful tool for assessing stroke risk in patients with atrial fibrillation and guiding decisions about anticoagulation therapy. However, the score should be used in conjunction with clinical judgment and individualized patient assessment.",
      "language": "en",
      "sentiment": {
        "neg": 0.12,
        "neu": 0.811,
        "pos": 0.069,
        "compound": -0.8078
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 268,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 37,
        "adj_adv_ratio": 0.13805970149253732,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 268
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 19.142857142857142,
          "clause_complexity": 0.14285714285714285,
          "vocabulary_richness": 0.5895522388059702
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 3,
            "contrast": 2,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBG": 7,
            "VBZ": 7,
            "VB": 5,
            "VBN": 6,
            "VBP": 2,
            "VBD": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      }
    },
    {
      "from": "human",
      "value": "Can you recap the Apple Heart Study ? And tell me what they have found ?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.767,
        "pos": 0.233,
        "compound": 0.6767
      },
      "core_lexical": {
        "self_ref_freq": 1,
        "second_person_freq": 1,
        "token_count": 16,
        "self_ref_ratio": 0.0625,
        "second_person_ratio": 0.0625
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 1,
        "self_ref_ratio": 0.0625,
        "second_person_freq": 1,
        "second_person_ratio": 0.0625,
        "token_count": 16
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 8.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 1,
            "how": 0,
            "why": 0,
            "can_could": 1,
            "general": 2
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 2,
            "VBP": 1,
            "VBN": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 1
    },
    {
      "from": "gpt",
      "value": "The Apple Heart Study was a large-scale clinical trial conducted by Apple in collaboration with Stanford Medicine to evaluate the accuracy of the Apple Watch for detecting atrial fibrillation (AF). The study enrolled over 400,000 participants aged 22 years or older, who owned an Apple Watch and an iPhone. Participants were required to download an app that used photoplethysmography (PPG) sensors in the Watch to detect irregular heart rhythms, including AF. When an irregular rhythm was detected, participants received a notification and were asked to complete a telemedicine consultation with a physician through the app.\n\nThe study found that:\n\n1. The Watch was able to detect AF with a sensitivity of 84% and a specificity of 71%. This means that the Watch was able to correctly identify 84% of participants with AF and 71% of participants without AF.\n2. AF detection rates were higher in older participants and in those with a history of cardiovascular disease.\n3. Only a small proportion of participants who received an irregular rhythm notification had AF confirmed by subsequent medical evaluation (only about a third of them).\n4. The telemedicine consultations were effective in identifying AF and other cardiovascular conditions, and most participants reported high satisfaction with the consultations.\n\nOverall, the Apple Heart Study suggested that the Watch may be a useful tool for AF screening, especially in high-risk populations, and that telemedicine consultations can be an effective means of evaluating and managing patients with suspected AF. However, the study also highlighted the importance of clinical confirmation and appropriate follow-up for irregular rhythm notifications, as the accuracy of the Watch for detecting AF is not perfect, and false positives and false negatives can occur.",
      "language": "en",
      "sentiment": {
        "neg": 0.016,
        "neu": 0.883,
        "pos": 0.101,
        "compound": 0.979
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 315,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 41,
        "adj_adv_ratio": 0.13015873015873017,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 315
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 21.0,
          "clause_complexity": 0.06666666666666667,
          "vocabulary_richness": 0.6415094339622641
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 2,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 1,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBD": 18,
            "VBN": 6,
            "VB": 10,
            "VBG": 6,
            "VBZ": 2
          },
          "named_entities": {
            "ORGANIZATION": 9,
            "PERSON": 2,
            "GPE": 5
          }
        }
      }
    },
    {
      "from": "human",
      "value": "Can you give me the major differences between the new 2020 recommendations and the 2016 recommendations ?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 1,
        "second_person_freq": 1,
        "token_count": 17,
        "self_ref_ratio": 0.058823529411764705,
        "second_person_ratio": 0.058823529411764705
      },
      "lexical_features": {
        "adj_adv_freq": 2,
        "adj_adv_ratio": 0.11764705882352941,
        "self_ref_freq": 1,
        "self_ref_ratio": 0.058823529411764705,
        "second_person_freq": 1,
        "second_person_ratio": 0.058823529411764705,
        "token_count": 17
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 17.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.875
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 1,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 1
          },
          "named_entities": {}
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 1
    },
    {
      "from": "gpt",
      "value": "Yes, here are some of the major differences between the 2020 and 2016 ESC guidelines for the management of atrial fibrillation (AF):\n\n1. Risk assessment: The 2020 guidelines recommend using the CHA2DS2-VASc score for stroke risk assessment, rather than the CHA2DS2-VASc or CHADS2 score used in the 2016 guidelines. The CHA2DS2-VASc score includes additional risk factors, such as vascular disease and female sex, and has been shown to be more accurate in predicting stroke risk in AF patients.\n2. Anticoagulation: The 2020 guidelines recommend considering oral anticoagulation (OAC) for stroke prevention in all patients with a CHA2DS2-VASc score of 1 or higher, whereas the 2016 guidelines recommended OAC only for scores of 2 or higher. The 2020 guidelines also provide updated recommendations on the choice and dosing of OACs, as well as guidance on the management of bleeding complications.\n3. Rate and rhythm control: The 2020 guidelines suggest that rate control should be the first-line approach for most patients with AF, whereas the 2016 guidelines gave equal weight to rate and rhythm control strategies. The 2020 guidelines also provide updated recommendations on rate control medications and target heart rates. Additionally, the 2020 guidelines recommend considering catheter ablation as a first-line therapy for selected patients with paroxysmal AF and no structural heart disease, whereas the 2016 guidelines reserved catheter ablation for patients with refractory symptoms or intolerant of pharmacological therapy.\n4. Screening and diagnosis: The 2020 guidelines provide new recommendations on the use of screening tools, such as handheld ECG devices and mobile health technologies, for the detection of AF in asymptomatic patients. The guidelines also recommend the use of extended cardiac monitoring (up to 30 days) in patients with suspected paroxysmal AF, rather than the 24-hour Holter monitoring recommended in the 2016 guidelines.\n5. Management of special populations: The 2020 guidelines provide updated recommendations on the management of AF in special populations, such as patients with heart failure, valvular heart disease, and renal impairment. The guidelines also include new recommendations on the management of AF in patients with cancer and those undergoing cardiac surgery.\n\nOverall, the 2020 guidelines provide updated and more detailed recommendations on the management of AF, with a focus on individualized, patient-centered care based on the best available evidence.",
      "language": "en",
      "sentiment": {
        "neg": 0.057,
        "neu": 0.838,
        "pos": 0.105,
        "compound": 0.9649
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 419,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 59,
        "adj_adv_ratio": 0.14081145584725538,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 419
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 24.647058823529413,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.5194805194805194
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 3,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 10,
            "VBG": 6,
            "VBN": 5,
            "VBZ": 2,
            "VB": 4,
            "VBD": 5
          },
          "named_entities": {
            "ORGANIZATION": 7
          }
        }
      }
    }
  ],
  "overall_sentiment": {
    "compound": 0.24490714285714285,
    "pos": 0.07464285714285715,
    "neu": 0.8867857142857141,
    "neg": 0.038571428571428576
  },
  "overall_lexical": {
    "adj_adv_freq": 237,
    "adj_adv_ratio": 0.12929623567921442,
    "self_ref_freq": 7,
    "self_ref_ratio": 0.0038188761593016913,
    "second_person_freq": 7,
    "second_person_ratio": 0.0038188761593016913,
    "total_tokens": 1833
  },
  "overall_advanced": {
    "structural_features": {
      "avg_sentence_length": 17.327196333078685,
      "clause_complexity": 0.016117216117216115,
      "vocabulary_richness": 0.7963861190279723
    },
    "interaction_features": {
      "question_types": {
        "what": 3,
        "how": 2,
        "why": 0,
        "can_could": 7,
        "general": 8
      },
      "discourse_markers": {
        "elaboration": 8,
        "contrast": 5,
        "causality": 0,
        "hedging": 0
      }
    },
    "linguistic_features": {
      "verb_tense_dist": {
        "VB": 45,
        "VBP": 41,
        "VBD": 27,
        "VBN": 33,
        "VBG": 32,
        "VBZ": 23
      },
      "named_entities": {
        "GPE": 8,
        "ORGANIZATION": 37,
        "PERSON": 4
      }
    }
  },
  "conversation_metadata": {
    "language_distribution": {
      "fi": 1,
      "en": 13
    },
    "turn_count": 14,
    "total_tokens": 1833
  }
}